The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

NCT06930118 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Advanced Colorectal Cancer in the Third-line Treatment and Beyond
pMMR/MSS Advanced Colorectal Cancer

Interventions

DRUG: chidamide, regorafenib, and iparomlimab/tuvonralimab

Sponsor

Shanghai Changzheng Hospital